# Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics

> **NCT06980454** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 322 (estimated)

## Conditions studied

- Cancer
- mCRC

## Interventions

- **DRUG:** HLX05
- **DRUG:** EU-Erbitux®
- **DRUG:** US-Erbitux®
- **DRUG:** CN-Erbitux®

## Key facts

- **NCT ID:** NCT06980454
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980454, "Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06980454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*